Trial Profile
A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Pamiparib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- 05 Jul 2022 Planned End Date changed from 30 Jul 2027 to 30 Jul 2029.
- 05 Jul 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2024.
- 01 Sep 2021 Planned End Date changed from 1 Jul 2027 to 30 Jul 2027.